Menu Search
Equities

Kissei Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KSPHF:PKL

Kissei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.97
  • Today's Change0.00 / 0.00%
  • Shares traded400.00
  • 1 Year change--
  • Beta0.3376
Data delayed at least 15 minutes, as of Dec 08 2025 19:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kissei Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through four segments. The Pharmaceutical segment manufactures and sells prescription drugs, and also purchases and sells healthcare foods such as prescription drugs and foods for special medical purposes. The Goods Sales segment is engaged in the development, production and sale of noodles, the sale of various equipment, vehicles and fuel, as well as insurance agency business. The Information Services segment operates in three areas including system integration services, system resource services such as information-related equipment rental and network construction, and medical system development and sales. The Construction and Facility Maintenance segment provides comprehensive construction services ranging from building construction to the maintenance and management of equipment and facilities.

  • Revenue in JPY (TTM)95.29bn
  • Net income in JPY14.14bn
  • Incorporated1946
  • Employees1.78k
  • Location
    Kissei Pharmaceutical Co Ltd19-48, YoshinoMATSUMOTO-SHI 399-8710JapanJPN
  • Phone+81 263259081
  • Fax+81 263257899
  • Websitehttps://www.kissei.co.jp
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.